Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

) who converted to normal heart rhythm within 90 minutes, the median time to conversion was 12 minutes from the initiation of dosing.

"We are delighted to see a 47% conversion rate in post-operative atrial fibrillation patients, and in particular we are encouraged by the safety profile observed in this fragile patient population," stated Bob Rieder, Chief Executive Officer and Chairman of Cardiome. "The efficacy and safety results observed in this study are consistent with those we've seen throughout the vernakalant (iv) development program."

The ACT 2 study was conducted in 42 centres in the United States, Canada, Argentina, India and Europe. The study was focused on the treatment of patients with atrial fibrillation or atrial flutter occurring after CABG or valve replacement surgery. Approximately 30% of these patients have an episode of atrial arrhythmia following their surgery. The arrhythmia, though transient, is a significant medical concern.

"We are very pleased with the results of the ACT 2 trial and the important insight it provides about the use of vernakalant (iv)," stated Yoshihiko Hatanaka, President and Chief Executive Officer of Astellas Pharma US, Inc.

In October 2003, Cardiome granted Astellas Pharma US, Inc. an exclusive license to develop and commercialize vernakalant (iv) in North America. The companies have co-developed vernakalant (iv) to NDA, with Astellas responsible for 75% of development costs. Cardiome has retained all rights to the intravenous formulations outside of Canada, U.S. and Mexico.

Cardiome will hold a conference call and webcast on Monday, June 4, 2007 at 9:00am EDT (6:00am PDT). Please dial 416-340-8010 or 866-540-8136 to access the call. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the presentation. The webcast can be accessed through Cardiome's website at www.cardiome.com. Webca
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:6/19/2013)... , June 19, 2013 A decade-long JDRF-funded ... Helmholtz Zentrum München, Germany , is ... and the risk of developing type 1 diabetes (T1D), ... for the disease. The study, "Seroconversion to Multiple Islet ... was published today in The Journal of the ...
(Date:6/19/2013)... 2013   Voices Against Brain Cancer (VABC), ... brain cancer, today announced that it has awarded Tocagen ... clinical investigation of Toca 511 & Toca FC in ... cancer (Grade 3 or Grade 4).  Tocagen is a ... cancer, with an initial focus on brain cancer. ...
(Date:6/19/2013)... 2013 Amerivet Solutions, LLC ( AMERIVET ... of government from Federal to Municipal, is pleased ... to include complex metal design and fabrication manufacturing. ... complex aluminum parts for the Defense Logistics Agency ... to service government contracts," states Richard Bergen ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... Thomas, McNerney & Partners, LLC, a health care venture ... technology companies, will be relocating its West Coast office ... Pratik Shah, Ph.D. announced the move at BIOCOM,s first ... "Southern California is home to many top-tier scientific ...
... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
Cached Medicine Technology:Thomas, McNerney & Partners Expands Team and Moves West Coast Office to San Diego 2Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s indoor ... Saver kit at an exceptional price. The 5-2-1 Compressor Saver ... conditioning unit during start up, saving wear and tear on ... burn out. , The 5-2-1 Compressor Saver works ... less power to start and drastically reduces the rush of ...
(Date:6/19/2013)... Beverly Hills, CA (PRWEB) June 19, 2013 ... Beverly Hills, permits some patients to quit using drugs ... Kern and Adi Jaffe, the founders of Alternatives, believe ... “hit Bottom” before they enter treatment and that this ... that 22 million people in the United States need ...
(Date:6/19/2013)... City, MO (PRWEB) June 19, 2013 Kansas City ... part of Main Street Day . A section of Main ... pedestrian traffic during the afternoon of the event. The Main ... host the event, which will help Kansas City join the ranks ... used Ciclovia as a tool to foster community vibrancy and active ...
(Date:6/19/2013)... Bellingham, Washington (PRWEB) June 19, 2013 ... before physicians deem it medically necessary, according to ... Maternal and Child Health Journal. The results of ... advocating for more than a decade – that ... care, and maintaining a healthy body weight. Fairhaven ...
(Date:6/19/2013)... June 19, 2013 In 2011, the ... EUR 710 million. Generic drugs form the largest sector, ... value. The pharmaceutical industry is a significant contributor to ... the country’s GDP. Approximately 50% of the total domestic ... pharmaceutical industry. Hemofarm, Galenika and Zdravlje Actavis are key ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2
... in March , , DETROIT, June 30 The National ... the blind in the United States, will hold its third March ... City March for Independence is a 5K walk held as part ... place in Detroit this year. Over one thousand blind Americans, ...
... an unmitigated success, welcoming 1012 visitors who left the show impressed ... June 30 A total success. That ... Summit , held for the first time on June 15-16, 2009 ... exhibition welcomed over 1000 key decision-makers in the food industry, in ...
... contribute to solving the world,s major problems over the next five ... special 25th anniversary edition of Issues in Science and Technology ... for science to deliver on its potential to enhance prosperity, security, ... respond. , , Vaclav Smil on the need ...
... medical device company Intelligent Hospital Systems (IH Systems) ... the Computerworld Honors Program Awards Gala on June ... the award in recognition of its RIVA System ... software, robotics and engineering to automate IV preparation ...
... 30 The Renal Physicians Association (RPA) supports Kidney ... in Kidney Care (PEAK) initiative. RPA is a member ... dialysis providers, physicians, manufacturers, and nurses who work together ... The goal of the PEAK campaign is to reduce ...
... found evidence that chronic disease in either a mother ... that are associated with the development of polycystic ovarian ... that brothers of women with PCOS and insulin resistance ... or diabetes, suggesting that factors associated with the condition ...
Cached Medicine News:Health News:Over One Thousand Blind Americans to March in Detroit 2Health News:Food Ingredients Industry Leaders Applaud the Launch of Health ingredients South America 2Health News:Food Ingredients Industry Leaders Applaud the Launch of Health ingredients South America 3Health News:Food Ingredients Industry Leaders Applaud the Launch of Health ingredients South America 4Health News:Articles by Prominent Scientists Featured in 25th Anniversary Issue 2Health News:Intelligent Hospital Systems Receives International Award for Innovative Technology Benefiting Society 2Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 2Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 3Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 4
Specimen mounts are designed to allow for the rotation of the specimen in the Vibratome vice assembly for sectioning at different horizontal orientations....
... provides a convenient reservoir of cooling water for the ... extended period of time or in a location which ... the hot side of the thermoelectric heat pump. ... is adequate to run the 900R for up to ...
Punch set for Advanced Tissue Arrayer, 2.0 mm...
Inquire...
Medicine Products: